The versatility of the dGH platform enables it to provide value in numerous areas of biomedical research. Learn more about dGH applications in a specific field by following one of the links below.
Through structural analysis of baseline and edited cell populations, dGH is able to help optimize editing processes, quantify and identify on/off-target effects, and provide a crucial metric for quality control in editing trials and experiments.
dGH has already helped identify previously undetected structural errors in patients. It enables clinicians and researchers to screen for rare chromosomal mutations and variants that other cytogenomic methods are unable to detect.
dGH assays provide single cell analysis that reliably detects low-frequency, complex variations in heterogeneous cell populations, making it ideal for identifying potentially oncogenic mutations.
KromaTiD was founded on a grant from NASA which facilitated the development of dGH in order to track ionizing radiation induced DNA damage. dGH is capable of providing the foundation for multiple dose response assays including inversions, dicentrics and translocations.
Cellular reagent delivery can result in unintended genomic consequences. dGH gives researchers a simple method for detecting and quantifying structural damage associated with experimental delivery conditions.